What is the role of current mass spectrometry in pharmaceutical analysis?

Abstract

The role of mass spectrometry (MS) has become more important in most application domains in recent years. Pharmaceutical analysis is specific due to its stringent regulation procedures, the need for good laboratory/manufacturing practices, and a large number of routine quality control analyses to be carried out. The role of MS is, therefore, very different throughout the whole drug development cycle. While it dominates within the drug discovery and development phase, in routine quality control, the role of MS is minor and indispensable only for selected applications. Moreover, its role is very different in the case of analysis of small molecule pharmaceuticals and biopharmaceuticals. Our review explains the role of current MS in the analysis of both small‐molecule chemical drugs and biopharmaceuticals. Important features of MS‐based technologies being implemented, method requirements, and related challenges are discussed. The differences in analytical procedures for small molecule pharmaceuticals and biopharmaceuticals are pointed out. While a single method or a small set of methods is usually sufficient for quality control in the case of small molecule pharmaceuticals and MS is often not indispensable, a large panel of methods including extensive use of MS must be used for quality control of biopharmaceuticals. Finally, expected development and future trends are outlined.

A Review of Advances in Bioanalytical Methods for the Detection and Quantification of Olanzapine and Its Metabolites in Complex Biological Matrices

“…Therefore, so far eagerly used in LC-ECD and LC-UV analyses, phosphate buffer is not suitable for detection by mass spectrometry. It induces ion suppression and gives a high baseline background [ 123 ]. Ion suppression leads to an artificial and unreproducible reduction in the olanzapine signal when the constant concentration assay is performed on samples where the background electrolyte concentration changes.…”

Identifying the Transients and Transformation Products in Hydroxyl Radical–Methimazole Reactions Using DFT and UPLC-Q-TOF MS/MS Approaches

“…Analysis of transformation products (TPs), particularly neutral species formed from transient species during the second phase of radical–molecule reactions, is a vital component of research in biology and environmental science, especially for the remediation of hazardous materials in the environment using advanced oxidation methods. − The transformation reactions can primarily be radical–radical recombination, elimination, or substitutions; they can produce a significant number of products whose nature can be strongly influenced by the solvent medium. The identification of drug metabolic/degradation products is crucial for pharmacokinetic studies as it allows to assess the safety and efficacy of drugs .…”

Traceability of cold medications with similar ingredients based on laser-induced breakdown spectroscopy

“…With the development of detection technology and machine learning, more and more researchers combined these with the classication of medications. Mass spectrometry (MS), 4,5 a traditional and outstanding elemental analysis technology, was used to study the quality control and efficacy of Calculus bovis combined with principal component analysis (PCA). 6 Zheng et al used near-infrared spectroscopy (NIR) combined with convolutional neural network (CNN) to identify multi-category and multimanufacturer medications.…”